Press Releases July 8, 2026 08:00 AM

Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026

Nautilus Biotechnology to Report Q2 2026 Financial Results and Host Conference Call on July 28

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
NAUT

Nautilus Biotechnology, Inc., a US-based life sciences company specializing in single-molecule protein analysis platform technology, announced it will release its second quarter 2026 financial results on July 28, 2026, before the market opens. The company will host a webcast conference call to discuss its financial results, business developments, and outlook.

Nautilus Biotechnology to Announce Second Quarter 2026  Financial Results on July 28, 2026
NAUT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Nautilus will announce Q2 2026 financial results on July 28, 2026 before market open.
  • A webcast conference call is scheduled to review results and business outlook.
  • The company focuses on pioneering single-molecule protein analysis technology impacting the proteomics and life sciences sectors.

SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter 2026 before market open on Tuesday, July 28, 2026.

The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Media Contact
[email protected]

Investor Contact
[email protected]


Risks

  • As a development stage company, Nautilus faces uncertainties related to commercialization and profitability of its proteomics platform.
  • Market reaction might be muted due to the company's early stage and potential volatility in biotech stocks.
  • The company's financial results may impact investor sentiment given the high-risk nature of biotechnology development.

More from Press Releases

Kinross to announce Q3 results on October 28, 2026 Oct 6, 2026 First Digital Signs Definitive Agreement to Become a Publicly Listed Company to Build the Infrastructure for the Agentic Economy Oct 6, 2026 Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply Oct 6, 2026 Midland States Bancorp Files Universal Shelf Registration Statement Oct 6, 2026 Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026 Oct 6, 2026